Artificial Intelligence

Hillstream BioPharma Announces Collaboration with Sapien Biosciences in Cancer Treatments

Published

2 years ago

June 27, 2022

BRIDGEWATER, N.J., June 27, 2022 (GLOBE NEWSWIRE) — Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, today announced a collaboration with Sapien Biosciences to evaluate the synergy of HSB-1216 with immune checkpoint inhibitors.

Immune Checkpoint Inhibitors and Ferroptosis

Treatment with immune checkpoint inhibitors (ICIs) induces the effector function of T cells in the tumor microenvironment (TME). Activated T cells accumulated in TME then kill tumor cells mainly by enhancing cell death through the granzyme pathway and by releasing interferon gamma (IFN) from CD8⁺ T cells. Ferroptosis is a newly defined form of cell death, that is different than apoptosis, necrosis or autophagy, and results from iron-dependent accumulation of lipid reactive oxygen species or lipid peroxidation.

Recent studies published [Nature, 569 (7755):270-274, 2019] describe that immunotherapy-activated CD8⁺ T cells enhance ferroptosis-specific lipid peroxidation in tumor cells leading to the anti-tumor effect of immunotherapy. Activated CD8⁺ T cells by treatment with ICIs promote tumor cell lipid peroxidation and thereby sensitize tumor cells to ferroptosis inducers through IFN. The study concluded that inducing the Ferroptotic pathway in combination with checkpoint blockade is a potential synergistic therapeutic approach.

“We are initiating studies, in collaboration with Sapien Biosciences, to determine the synergy between HSB-1216, our ferroptosis inducer and nivolumab, an anti-PD1 antibody,” said Randy Milby, Hillstream’s Chief Executive Officer. “In addition, we will also study the potential synergistic effects of HSB-1216 with the recently approved Bristol Myers Squibb drug Opdualag® (nivolumab + relatlimab), a fixed dose combination of an anti-PD1 MAb + anti-LAG3 MAb, to demonstrate that targeting a ferroptosis-associated metabolism in tumors may improve the efficacy of cancer immunotherapy.”

“We are excited to extend our collaboration with Hillstream Biopharma to evaluate potential synergy between their HSB-1216 molecule and ICIs using our expertise in establishing patient tissue-derived cell models in oncology, immunology and Immune-oncology,” said Dr. Jugnu Jain, CEO, Sapien Biosciences. “Previously, Sapien demonstrated potent anti-cancer activity of HSB-1216 in primary triple negative breast cancer cells which were presented at AACR 2020.”

About Hillstream BioPharma Inc.

Hillstream BioPharma, Inc. is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers. Hillstream’s most advanced candidate is HSB-1216, an IMCD modulator, targeting a variety of solid tumors. The active drug in HSB-1216 was found to be efficacious in a clinical pilot study in Germany in devastating cancers, including triple negative breast cancer and epithelial carcinomas. Hillstream intends to start a clinical study with HSB-1216 in 2022 to expand upon the existing early clinical proof-of-concept. Hillstream uses Quatramer™, our proprietary tumor targeting platform, to enhance the uptake of HSB-1216 in the tumor microenvironment with an extended duration of action and minimal off-target toxicity. In addition, Trident Artificial Intelligence, Hillstream’s artificial intelligence precision medicine platform, is used to identify biomarkers in our clinical programs to target a specific patient segment most likely to benefit. For more information, please visit www.hillstreambio.com.

About Sapien Biosciences Private Limited

Sapien Biosciences, founded in 2012 and headquartered in India, is a joint venture between Apollo Hospitals and Saarum Innovations that has created one of the 10- largest multi-disease biobanks in the world. Sapien uses its patient samples and rich datasets to help biotech companies validate novel drug targets, drugs and diagnostics that translate into better clinical outcomes. Sapien’s trademarked services and products include 1) Oncobloc^TM, a systematic collection of pathology blocks with complete demographic and diagnostic data, 2) OncoPrime^TM, a panel of primary cells derived from cancer patient tissues, cultured as 2D or 3D spheres to test novel drugs, 3) TruCell^TM, a panel of primary cells derived from all types of normal or disease samples such as cancer-associated fibroblasts, dendritic cells, 4) TruSkin^TM , cell & molecular assays using normal human skin to test novel formulations and drugs, 5) TruData^TM , real world treatment and outcomes data of Indian cancer patients including genotype data, and 6) Clinical diagnostics that are developed at Sapien or with partners to personalize therapy.
For more information, please visit: https://sapienbio.co.in/

Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Hillstream’s expectations, strategy, plans or intentions. These forward-looking statements are based on Hillstream’s current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions, including the outbreak of COVID-19 coronavirus, which could seriously harm our financial condition and increase our costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Investors should read the risk factors set forth in our Form 10-K for the year ended December 31, 2021 and our periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Hillstream does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.

Investor Relations Contact:
Email: [email protected]
www.hillstreambio.com

Related Topics:AI Artificial Intelligence Machine learning

Up Next

myDigitalOffice Acquires Datavision to Expand Hotel Performance & Analytics Footprint

Don't Miss

[24]7.ai Wins CCW Excellence Award for BPO of the Year

GlobeNewswire

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Eye Level holds its 2024 Eye Level Math Olympiad for students to test out their math skills.

Published

59 mins ago

October 18, 2024

CISION (PR Newswire)

eye-level-holds-its-2024-eye-level-math-olympiad-for-students-to-test-out-their-math-skills.

SEOUL, South Korea, Oct. 17, 2024 /PRNewswire/ — Eye Level is hosting the 2024 Math Olympiad (ELMO 2024), inviting students from grades 1 to 8 worldwide to showcase their math skills. The competition will run from November 9 to December 1, following each country’s schedule across 15 countries.object

This Olympiad, part of the annual Eye Level Math Olympiad series established in 2004, offers students a valuable opportunity to assess and enhance their mathematical abilities. The test lasts approximately one hour and is designed to challenge students across various areas of math skills, covering most arithmetic and critical thinking domains. Questions are tailored to each grade level, allowing students to evaluate their skills objectively.All participants will receive a certificate of participation and a comprehensive analysis of their test results. Official results and winners will be announced in January 2025 on myeyelevel.com, with award ceremonies planned to be held locally for outstanding participants.
Registration is currently open on myeyelevel.com.
About Eye Level
Eye Level is an international provider of supplemental education services in Math and English with more than 2 million students having experienced its programs. Eye Level guides the students to learn at their own pace, and achieve their goals. With a growth-minded learning process, Eye Level helps students build good learning habits that become the foundation of great talent – setting them up for success in school and beyond.
Photo – https://mma.prnewswire.com/media/2533165/p14_1_ELMO.jpg

View original content:https://www.prnewswire.co.uk/news-releases/eye-level-holds-its-2024-eye-level-math-olympiad-for-students-to-test-out-their-math-skills-302278994.html

Artificial Intelligence

n2 Group Advances HPC/AI Portfolio by Acquiring Managed Services Company X-ISS

Published

9 hours ago

October 17, 2024

CISION (PR Newswire)

OXFORD, England, Oct. 17, 2024 /PRNewswire/ — n2 Group, the transformative computing technology investment company, announces the acquisition of high-performance computing (HPC) and AI specialists, X-ISS. The addition of X-ISS expands the Group’s portfolio– joining NAG, VSNi, BioTeam and STAC—as it accelerates advancements in technology and computation, underpinned by innovation, technical excellence, and a focus on long-term growth.

n2 Group invests selectively in technical computing companies with deep business impact in a variety of sectors, providing operational support and a collaborative approach to innovation and business transformation. The addition of X-ISS will further strengthen the Group’s already strong HPC/AI credentials, with NAG, STAC and BioTeam already adding to this space.
X-ISS is a pioneer in Managed Services specifically designed for HPC/AI. With their in-depth understanding of hardware and software complexities within HPC and AI, they deliver highly impactful end-to-end services to clients through the integration, optimization and management of HPC/AI systems. The integration of X-ISS into n2 Group aligns with the Group vision of improving the accessibility, quality and robustness of computing solutions to enable greater productivity in industry.
X-ISS will operate as an autonomous business within the n2 Group, maintaining its brand, identity and ethos. n2 Group’s status as an independent, member-backed organisation with no external financial stakeholders allows X-ISS to continue providing impartial advice based on the technology needs and challenges of its clients. Inter-group synergies will enable greater innovation and collaboration, advancing the Group’s position and long-term HPC/AI market impact.
“X-ISS strengthens the n2 community in the strategically important area of HPC/AI”, said Adrian Scales, Snr Director of Investments and Partnerships at n2 Group. “As a respected boutique HPC service provider, X-ISS is helping clients navigate an increasingly complex landscape in terms of technologies and software integrations with AI and analytics. The acquisition strongly complements the Group’s existing HPC professional services capability, and we are delighted to have them on board.”
“This is an important milestone for X-ISS.”, said Deepak Khosla, CEO X-ISS, “The partnership with n2 Group will enable us to enhance our flagship ManagedHPC solution by leveraging n2’s complementary services and product developments, allowing us to deliver even greater value to our customers. As businesses face increasing challenges with complex technologies like AI and cloud computing, we’re now better equipped to support them with the same quality, passion, and partnership that defines X-ISS. I am excited about the opportunities this can bring for current and future X-ISS customers.”
About n2 Group 
At n2 Group we are transforming computing and technology investment with a radical new approach. Our businesses are all established, purpose-driven market-leaders in computing products or services. We stimulate long-term sustainable growth through group-level support in strategy, business development, innovation, and operations. With no shareholders or external financial interests, we reinvest all profits back into the group or to the community, reinforcing our commitment to positive social impact through technological advancements.   
n2 Group companies are at the forefront of computing and IT infrastructure, helping clients in various sectors to be more productive, innovative or reduce risk through advanced software and services. Rapidly expanding in high-performance computing, artificial intelligence, and scientific computing, our businesses maintain their unique brands and identities, but benefit from the expanded network available through the group.  
n2 Group Companies 
• BioTeam: Scientific computing consultancy integrating technologies, data, and cultures to accelerate science.
• NAG: Advanced products and services in algorithms, optimization, high-performance computing and AI.
• STAC: Independent financial services technology research and community events.
• VSNi: Proven statistical solutions and data expertise driving innovation and success. 
• X-ISS: Industry leading management and analytics solutions for HPC/AI systems.
For more detailed information and the latest updates, visit n2 Group.
Logo – https://mma.prnewswire.com/media/2271328/n2_Group_Logo.jpgLogo – https://mma.prnewswire.com/media/2533549/XISS_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/n2-group-advances-hpcai-portfolio-by-acquiring-managed-services-company-x-iss-302279433.html

Artificial Intelligence

TIE 2024 Unveils a New Era of Innovation

Published

11 hours ago

October 17, 2024

CISION (PR Newswire)

A New Era of AI-powered Innovation and Industrial Revolution: Driving Integration of Smart Tech into Daily Life.
TAIPEI, Oct. 17, 2024 /PRNewswire/ — The 2024 Taiwan Innotech Expo (TIE) kicked off today at Taipei World Trade Center with a focus on “Smart Tech Island –The New Era of AI.” This year’s event showcases over a thousand advanced technologies and research achievements across six key areas: digital information, data security, precision health, defense, green and renewable energy, and civil and military resilience, heralding a new chapter in the technological evolution of industries.

Online and On-Site Exhibitions Offers Comprehensive Access to the Latest Innovations
TIE 2024 offers a seamless blend of virtual and physical experiences. Visitors can explore technologies, register for events, and plan their visit online before the expo opens. During the expo period, the event website provides essential tools such as e-meeting requests, product maps, and program registration. For those who were unable to attend in person, online attendees can view exhibits and access business negotiation records even after the expo is closed, fostering ongoing collaboration and opportunities. As a leading platform for technological innovation exchanges in Taiwan, TIE 2024 showcases the nation’s advancements in AI and smart technologies. This event is anticipated to drive industry transformation and opens new chapters in technological innovation.
Official Website: https://tie.twtm.com.tw/en

View original content:https://www.prnewswire.co.uk/news-releases/tie-2024-unveils-a-new-era-of-innovation-302279310.html